恩扎卢胺联合雄激素剥夺治疗在非转移性去势抵抗性前列腺癌男性中显示一致的生存获益:PROSPER 试验按年龄和区域分组的亚组分析
PROSPER 试验的事后分析评估恩扎卢胺联合 ADT 在不同年龄和区域亚组中的 OS 获益与安全性。1401 名 nmCRPC 且 PSA 快速升高男性随机 2:1 接受恩扎卢胺 160 mg 或安慰剂。恩扎卢胺联合 ADT 降低死亡风险且不依赖年龄或区域,安全性在各亚组一致。
要点
- 恩扎卢胺联合 ADT 降低死亡风险,不受年龄(<70 vs ≥70 岁)或区域影响。
- 影响 OS 的显著因素包括 ECOG 状态(P < 0.0001)、log(PSA)(P = 0.0002)和后续治疗(P < 0.0001)。
- 安全性在各年龄和区域亚组中一致,任何级别 TEAE 在安慰剂组更常见且存在区域差异。
核心结论
- 在 PSA 快速升高的 nmCRPC 男性中,恩扎卢胺的获益和安全性在年龄和区域亚组间一致。
- 影响 OS 的变量包括 ECOG 状态、log(PSA) 和后续治疗。
研究设计与样本
- PROSPER 试验的事后分析,纳入 1401 名 nmCRPC 且 PSA 倍增时间 ≤10 个月、PSA ≥2 ng/mL 并持续使用 ADT 的男性。
- 患者随机 2:1 接受恩扎卢胺 160 mg 或安慰剂。
- 按年龄(<70 vs ≥70 岁)和区域(北美、欧洲、亚洲或世界其他地区)分析 OS 和安全性,并评估既往和后续治疗的影响。
主要发现
- 恩扎卢胺联合 ADT 降低死亡风险,不依赖年龄或区域。
- 多因素分析显示 ECOG 状态(P < 0.0001)、log(PSA)(P = 0.0002)和后续治疗(P < 0.0001)是影响 OS 的统计学显著因素。
- 安全性在各年龄和区域亚组中一致。
- 任何级别治疗中出现的不良事件在各年龄组间相似,在安慰剂组更常见,且存在区域差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enzalutamide combined with androgen deprivation therapy (ADT) significantly prolonged metastasis-free survival and overall survival (OS) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) with rapidly rising prostate-specific antigen (PSA). The objective of this post hoc analysis of the PROSPER trial is to evaluate OS benefit and safety of enzalutamide in patients across age and regional subgroups. PATIENTS AND METHODS: Eligible men with nmCRPC, PSA doubling time ≤10 months and PSA ≥2 ng/mL with continued ADT use were randomised 2:1 to enzalutamide 160 mg or placebo. OS and safety were examined by age (<70 vs ≥70 years) and region (North America, Europe, Asia or the rest of the world). The impact of prior and subsequent therapy was also examined. RESULTS: In total, 1401 men were enrolled (median age, 74 years). Enzalutamide plus ADT reduced the risk of death, independent of age or region. Multivariate analyses identified Eastern Cooperative Oncology Group (ECOG) status (P < 0.0001), log (PSA; P = 0.0002) and subsequent therapy (P < 0.0001) as statistically significant factors impacting OS. Safety was consistent across age and regional subgroups. Any grade treatment-emergent adverse events were similar across age groups, were more common in the placebo group and had regional variation. CONCLUSIONS: In men with nmCRPC and rapidly rising PSA, the benefit and safety of enzalutamide were consistent across age and regional subgroups. Variables impacting OS included ECOG status, log (PSA) and subsequent therapy. CLINICALTRIALS. GOV IDENTIFIER: NCT02003924.
引用
- De Giorgi U, Hussain M, Shore N, et al. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. Eur J Cancer. 2021. PMID: 34784577. doi:10.1016/j.ejca.2021.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。